These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24213855)

  • 1. Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles.
    Lebraud H; Coxon CR; Archard VS; Bawn CM; Carbain B; Matheson CJ; Turner DM; Cano C; Griffin RJ; Hardcastle IR; Baisch U; Harrington RW; Golding BT
    Org Biomol Chem; 2014 Jan; 12(1):141-8. PubMed ID: 24213855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.
    Matheson CJ; Coxon CR; Bayliss R; Boxall K; Carbain B; Fry AM; Hardcastle IR; Harnor SJ; Mas-Droux C; Newell DR; Richards MW; Sivaprakasam M; Turner D; Griffin RJ; Golding BT; Cano C
    RSC Med Chem; 2020 Jun; 11(6):707-731. PubMed ID: 33479670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates.
    Wong C; Griffin RJ; Hardcastle IR; Northen JS; Wang LZ; Golding BT
    Org Biomol Chem; 2010 May; 8(10):2457-64. PubMed ID: 20448906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the adenosinergic system in lung fibrosis.
    Della Latta V; Cabiati M; Rocchiccioli S; Del Ry S; Morales MA
    Pharmacol Res; 2013 Oct; 76():182-9. PubMed ID: 23994158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Characterization of an Irreversible Inhibitor of CDK2.
    Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
    Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided design of purine-based probes for selective Nek2 inhibition.
    Coxon CR; Wong C; Bayliss R; Boxall K; Carr KH; Fry AM; Hardcastle IR; Matheson CJ; Newell DR; Sivaprakasam M; Thomas H; Turner D; Yeoh S; Wang LZ; Griffin RJ; Golding BT; Cano C
    Oncotarget; 2017 Mar; 8(12):19089-19124. PubMed ID: 27833088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.
    Frett B; Brown RV; Ma M; Hu W; Han H; Li HY
    J Med Chem; 2014 Jul; 57(14):5835-44. PubMed ID: 24517277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling-TMS-deprotection-CuAAC sequence.
    Merkul E; Klukas F; Dorsch D; Grädler U; Greiner HE; Müller TJ
    Org Biomol Chem; 2011 Jul; 9(14):5129-36. PubMed ID: 21625704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3).
    Lum C; Kahl J; Kessler L; Kucharski J; Lundström J; Miller S; Nakanishi H; Pei Y; Pryor K; Roberts E; Sebo L; Sullivan R; Urban J; Wang Z
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3578-81. PubMed ID: 18502127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folded conformations due to arene interactions in dissymmetric and symmetric butylidene-linker models based on pyrazolo[3,4-d]pyrimidine, purine and 7-deazapurine.
    Avasthi K; Shukla L; Kant R; Ravikumar K
    Acta Crystallogr C Struct Chem; 2014 Jun; 70(Pt 6):555-61. PubMed ID: 24898957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
    Nekardová M; Vymětalová L; Khirsariya P; Kováčová S; Hylsová M; Jorda R; Kryštof V; Fanfrlík J; Hobza P; Paruch K
    Chemphyschem; 2017 Apr; 18(7):785-795. PubMed ID: 28128514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of
    Zhu Y; Ma Y; Zu W; Song J; Wang H; Zhong Y; Li H; Zhang Y; Gao Q; Kong B; Xu J; Jiang F; Wang X; Li S; Liu C; Liu H; Lu T; Chen Y
    J Med Chem; 2020 Jul; 63(13):6748-6773. PubMed ID: 32479083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
    Yang J; Wang LJ; Liu JJ; Zhong L; Zheng RL; Xu Y; Ji P; Zhang CH; Wang WJ; Lin XD; Li LL; Wei YQ; Yang SY
    J Med Chem; 2012 Dec; 55(23):10685-99. PubMed ID: 23116168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.
    Loidreau Y; Deau E; Marchand P; Nourrisson MR; Logé C; Coadou G; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2015 Mar; 92():124-34. PubMed ID: 25549552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors.
    Xue Y; Wan PT; Hillertz P; Schweikart F; Zhao Y; Wissler L; Dekker N
    ChemMedChem; 2013 Nov; 8(11):1846-54. PubMed ID: 24039150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structural characterization of trivalent amino acid derived chiral phosphorus compounds.
    Hersh WH; Xu P; Simpson CK; Grob J; Bickford B; Hamdani MS; Wood T; Rheingold AL
    J Org Chem; 2004 Mar; 69(6):2153-63. PubMed ID: 15058965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.
    Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity probes for the GABA-gated chloride channel: selection of 5e-tert-butyl-2e-[4-(substituted-ethynyl)phenyl]-1,3-dithianes and optimization of linker moiety.
    Li QX; Casida JE
    Bioorg Med Chem; 1995 Dec; 3(12):1667-74. PubMed ID: 8770391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible Nek2 kinase inhibitors with cellular activity.
    Henise JC; Taunton J
    J Med Chem; 2011 Jun; 54(12):4133-46. PubMed ID: 21627121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.